However, these studies have used various scoring methods and cut points for Ki67 IHC, have typically used surgical specimens for both Ki67 and the 21-gene assay, and have often not been restricted to patients intended for the recent IKWG recommendation (i.e., patients with ER+HER2− stage I/II breast cancer). This evidence concerns the gene MKI67 and breast carcinoma.